Abstract
The enteroendocrine system coordinates the physiological response to food intake by regulating rates of digestion, nutrient absorption, insulin secretion, satiation and satiety. Gut hormones with important anorexigenic and/or insulinotropic roles include glucagon-like peptide 1 (GLP-1), peptide YY (PYY3–36), cholecystokinin (CCK) and glucose-dependent insulinotropic peptide (GIP). High BMI or obesogenic diets do not markedly disrupt this enteroendocrine system, which represents a critical target for inducing weight loss and treating co-morbidities in individuals with obesity.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA, Bloom SR (2005a) The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res 1044:127–131. https://doi.org/10.1016/j.brainres.2005.03.011
Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA, Bloom SR (2005b) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake. Brain Res 1043:139–144. https://doi.org/10.1016/j.brainres.2005.02.065
Adam TC, Westerterp-Plantenga MS (2005) Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr 93:845–851. https://doi.org/10.1079/bjn20041335
Ahlkvist L, Brown K, Ahren B (2013) Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion. Endocr Connect 2:69–78. https://doi.org/10.1530/EC-12-0079
Ahlman H, Nilsson (2001) The gut as the largest endocrine organ in the body. Ann Oncol 12(Suppl 2):S63–S68. https://doi.org/10.1093/annonc/12.suppl_2.s63
Aranias T, Grosfeld A, Poitou C, Omar AA, Le Gall M, Miquel S, Garbin K, Ribeiro A, Bouillot JL, Bado A, Brot-Laroche E, Clement K, Leturque A, Guilmeau S, Serradas P (2015) Lipid-rich diet enhances L-cell density in obese subjects and in mice through improved L-cell differentiation. J Nutr Sci 4:e22. https://doi.org/10.1017/jns.2015.11
Asmar M, Simonsen L, Madsbad S, Stallknecht B, Holst JJ, Bulow J (2010) Glucose-dependent insulinotropic polypeptide may enhance fatty acid re-esterification in subcutaneous abdominal adipose tissue in lean humans. Diabetes 59:2160–2163. https://doi.org/10.2337/db10-0098
Baggio LL, Huang Q, Brown TJ, Drucker DJ (2004) Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546–558. https://doi.org/10.1053/j.gastro.2004.04.063
Bahrami J, Longuet C, Baggio LL, Li K, Drucker DJ (2010) Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 139:857–868. https://doi.org/10.1053/j.gastro.2010.05.006
Baldassano S, Bellanca AL, Serio R, Mule F (2012) Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2. J Endocrinol 213:277–284. https://doi.org/10.1530/JOE-12-0092
Baldassano S, Rappa F, Amato A, Cappello F, Mule F (2015) GLP-2 as beneficial factor in the glucose homeostasis in mice fed a high fat diet. J Cell Physiol 230:3029–3036. https://doi.org/10.1002/jcp.25039
Balks HJ, Holst JJ, von zur Muhlen A, Brabant G (1997) Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82:786–790. https://doi.org/10.1210/jcem.82.3.3816
Ballantyne GH (2006) Peptide YY(1-36) and peptide YY(3-36): part I. distribution, release and actions. Obes Surg 16:651–658. https://doi.org/10.1381/096089206776944959
Ballinger AB, Clark ML (1994) L-phenylalanine releases cholecystokinin (CCK) and is associated with reduced food intake in humans: evidence for a physiological role of CCK in control of eating. Metabolism 43:735–738. https://doi.org/10.1016/0026-0495(94)90123-6
Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M (2000) Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2:99–103. https://doi.org/10.1046/j.1463-1326.2000.00070.x
Barrera JG, Jones KR, Herman JP, D'Alessio DA, Woods SC, Seeley RJ (2011) Hyperphagia and increased fat accumulation in two models of chronic CNS glucagon-like peptide-1 loss of function. J Neurosci 31:3904–3913. https://doi.org/10.1523/JNEUROSCI.2212-10.2011
Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418:650–654. https://doi.org/10.1038/nature00887
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349:941–948. https://doi.org/10.1056/NEJMoa030204
Baumard L, Weerts Z, Masclee AAM, Keszthelyi D, Michael-Titus AT, Peiris M (2021) Effect of obesity on the expression of nutrient receptors and satiety hormones in the human colon. Nutrients 13. https://doi.org/10.3390/nu13041271
Bellono NW, Bayrer JR, Leitch DB, Castro J, Zhang C, O’Donnell TA, Brierley SM, Ingraham HA, Julius D (2017) Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell 170:185–198.e16. https://doi.org/10.1016/J.CELL.2017.05.034
Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH (2000) Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 47:112–119. https://doi.org/10.1136/gut.47.1.112
Billing LJ, Smith CA, Larraufie P, Goldspink DA, Galvin S, Kay RG, Howe JD, Walker R, Pruna M, Glass L, Pais R, Gribble FM, Reimann F (2018) Co-storage and release of insulin-like peptide-5, glucagon-like peptide-1 and peptideYY from murine and human colonic enteroendocrine cells. Mol Metab 16:65–75. https://doi.org/10.1016/J.MOLMET.2018.07.011
Boer GA, Keenan SN, Miotto PM, Holst JJ, Watt MJ (2021) GIP receptor deletion in mice confers resistance to high-fat diet-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism. Am J Physiol Endocrinol Metab 320:E835–E845. https://doi.org/10.1152/ajpendo.00646.2020
Bradwejn J, Koszycki D (2001) Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 234:19–27
Brierley DI, Holt MK, Singh A, de Araujo A, McDougle M, Vergara M, Afaghani MH, Lee SJ, Scott K, Maske C, Langhans W, Krause E, de Kloet A, Gribble FM, Reimann F, Rinaman L, de Lartigue G, Trapp S (2021) Central and peripheral GLP-1 systems independently suppress eating. Nat Metab 3:258–273. https://doi.org/10.1038/s42255-021-00344-4
Brighton CA, Rievaj J, Kuhre RE, Glass LL, Schoonjans K, Holst JJ, Gribble FM, Reimann F (2015) Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein–coupled bile acid receptors. Endocrinology 156:3961–3970. https://doi.org/10.1210/en.2015-1321
Burness CB, McCormack PL (2013) Teduglutide: a review of its use in the treatment of patients with short bowel syndrome. Drugs 73:935–947. https://doi.org/10.1007/s40265-013-0070-y
Carr RD, Larsen MO, Jelic K, Lindgren O, Vikman J, Holst JJ, Deacon CF, Ahren B (2010) Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 95:872–878. https://doi.org/10.1210/jc.2009-2054
Chelikani PK, Haver AC, Reidelberger RD (2004) Comparison of the inhibitory effects of PYY(3-36) and PYY(1-36) on gastric emptying in rats. Am J Physiol Regul Integr Comp Physiol 287:R1064–R1070. https://doi.org/10.1152/ajpregu.00376.2004
Chia CW, Carlson OD, Kim W, Shin YK, Charles CP, Kim HS, Melvin DL, Egan JM (2009) Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 58:1342–1349. https://doi.org/10.2337/db08-0958
Chia CW, Carlson OD, Liu DD, Gonzalez-Mariscal I, Santa-Cruz Calvo S, Egan JM (2017) Incretin secretion in humans is under the influence of cannabinoid receptors. Am J Physiol Endocrinol Metab 313:E359–E366. https://doi.org/10.1152/ajpendo.00080.2017
Chimerel C, Emery E, Summers DK, Keyser U, Gribble FM, Reimann F (2014) Bacterial metabolite indole modulates incretin secretion from intestinal enteroendocrine L cells. Cell Rep 9:1202–1208. https://doi.org/10.1016/j.celrep.2014.10.032
Christensen LW, Kuhre RE, Janus C, Svendsen B, Holst JJ (2015) Vascular, but not luminal, activation of FFAR1 (GPR40) stimulates GLP-1 secretion from isolated perfused rat small intestine. Physiol Rep 3. https://doi.org/10.14814/phy2.12551
Creutzfeldt W, Ebert R, Willms B, Frerichs H, Brown JC (1978) Gastric inhibitory polypeptide (GIP) and insulin in obesity: increased response to stimulation and defective feedback control of serum levels. Diabetologia 14:15–24. https://doi.org/10.1007/BF00429703
de Heer J, Rasmussen C, Coy DH, Holst JJ (2008) Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia 51:2263–2270. https://doi.org/10.1007/s00125-008-1149-y
de Lartigue G, Barbier de la Serre C, Espero E, Lee J, Raybould HE (2012) Leptin resistance in vagal afferent neurons inhibits cholecystokinin signaling and satiation in diet induced obese rats. PLoS One 7:e32967. https://doi.org/10.1371/journal.pone.0032967
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ (1995) Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 44:1126–1131. https://doi.org/10.2337/diab.44.9.1126
Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J, Beglinger C (2005) Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129:1430–1436. https://doi.org/10.1053/j.gastro.2005.09.001
Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696–1705. https://doi.org/10.1016/S0140-6736(06)69705-5
Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 84:3434–3438. https://doi.org/10.1073/pnas.84.10.3434
Drucker DJ, Erlich P, Asa SL, Brubaker PL (1996) Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 93:7911–7916. https://doi.org/10.1073/pnas.93.15.7911
Duca FA, Zhong L, Covasa M (2013) Reduced CCK signaling in obese-prone rats fed a high fat diet. Horm Behav 64:812–817. https://doi.org/10.1016/j.yhbeh.2013.09.004
Dupre J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37:826–828. https://doi.org/10.1210/jcem-37-5-826
Dusaulcy R, Handgraaf S, Skarupelova S, Visentin F, Vesin C, Heddad-Masson M, Reimann F, Gribble F, Philippe J, Gosmain Y (2016) Functional and molecular adaptations of enteroendocrine L-cells in male obese mice are associated with preservation of pancreatic alpha-cell function and prevention of hyperglycemia. Endocrinology 157:3832–3843. https://doi.org/10.1210/en.2016-1433
Eissele R, Koop H, Arnold R (1990) Effect of peptide YY on gastric acid secretion, gastrin and somatostatin release in the rat. Z Gastroenterol 28:129–131
Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Goke B (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Investig 22:283–291. https://doi.org/10.1111/j.1365-2362.1992.tb01464.x
Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V (1993) Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 138:159–166. https://doi.org/10.1677/joe.0.1380159
Faerch K, Torekov SS, Vistisen D, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T, Lauritzen T, Sandbaek A, Holst JJ, Jorgensen ME (2015) GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study. Diabetes 64:2513–2525. https://doi.org/10.2337/db14-1751
Feinle C, Chapman IM, Wishart J, Horowitz M (2002) Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 23:1491–1495. https://doi.org/10.1016/s0196-9781(02)00087-6
Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5:209ra151. https://doi.org/10.1126/scitranslmed.3007218
Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A (2018) Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet 392:2180–2193. https://doi.org/10.1016/S0140-6736(18)32260-8
Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A et al (1991) Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101:503–511. https://doi.org/10.1016/0016-5085(91)90031-f
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alanentalo T, Baquero AF, Buckley ST, Farkas E, Fekete C, Frederiksen KS, Helms HCC, Jeppesen JF, John LM, Pyke C, Nohr J, Lu TT, Polex-Wolf J, Prevot V, Raun K, Simonsen L, Sun G, Szilvasy-Szabo A, Willenbrock H, Secher A, Knudsen LB, Hogendorf WFJ (2020) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5. https://doi.org/10.1172/jci.insight.133429
Glicksman C, Pournaras DJ, Wright M, Roberts R, Mahon D, Welbourn R, Sherwood R, Alaghband-Zadeh J, le Roux CW (2010) Postprandial plasma bile acid responses in normal weight and obese subjects. Ann Clin Biochem 47:482–484. https://doi.org/10.1258/acb.2010.010040
Gniuli D, Calcagno A, Dalla Libera L, Calvani R, Leccesi L, Caristo ME, Vettor R, Castagneto M, Ghirlanda G, Mingrone G (2010) High-fat feeding stimulates endocrine, glucose-dependent insulinotropic polypeptide (GIP)-expressing cell hyperplasia in the duodenum of Wistar rats. Diabetologia 53:2233–2240. https://doi.org/10.1007/s00125-010-1830-9
Goldspink DA, Lu VB, Billing LJ, Larraufie P, Tolhurst G, Gribble FM, Reimann F (2018) Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells. Mol Metab 7:90–101. https://doi.org/10.1016/J.MOLMET.2017.11.005
Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, Beglinger C (1999) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Phys 276:R1541–R1544. https://doi.org/10.1152/ajpregu.1999.276.5.R1541
Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CAM, Parker HE, Morley TCE, Yeo GSH, Reimann F, Gribble FM (2012) Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153:3054–3065. https://doi.org/10.1210/en.2011-2170
Halatchev IG, Cone RD (2005) Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1:159–168. https://doi.org/10.1016/j.cmet.2005.02.003
Hansen L, Deacon CF, Orskov C, Holst JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140:5356–5363. https://doi.org/10.1210/endo.140.11.7143
Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ (2000) Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 278:E1010–E1018. https://doi.org/10.1152/ajpendo.2000.278.6.E1010
Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ (2010) The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes 59:1765–1770. https://doi.org/10.2337/db09-1414
Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56:117–126. https://doi.org/10.1159/000201231
Herrmann-Rinke C, Horsch D, McGregor GP, Goke B (1996) Galanin is a potent inhibitor of glucagon-like peptide-1 secretion from rat ileum. Peptides 17:571–576. https://doi.org/10.1016/0196-9781(96)00072-1
Hisadome K, Reimann F, Gribble FM, Trapp S (2010) Leptin directly depolarizes preproglucagon neurons in the nucleus tractus solitarius: electrical properties of glucagon-like peptide 1 neurons. Diabetes 59:1890–1898. https://doi.org/10.2337/db10-0128
Hisadome K, Reimann F, Gribble FM, Trapp S (2011) CCK stimulation of GLP-1 neurons involves alpha1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 60:2701–2709. https://doi.org/10.2337/db11-0489
Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52:199–207. https://doi.org/10.1007/s00125-008-1195-5
Holst JJ, Windelov JA, Boer GA, Pedersen J, Svendsen B, Christensen M, Torekov S, Asmar M, Hartmann B, Nissen A (2016) Searching for the physiological role of glucose-dependent insulinotropic polypeptide. J Diabetes Investig 7(Suppl 1):8–12. https://doi.org/10.1111/jdi.12488
Holt MK, Richards JE, Cook DR, Brierley DI, Williams DL, Reimann F, Gribble FM, Trapp S (2019) Preproglucagon neurons in the nucleus of the solitary tract are the main source of brain GLP-1, mediate stress-induced hypophagia, and limit unusually large intakes of food. Diabetes 68:21–33. https://doi.org/10.2337/db18-0729
Hou Y, Ernst SA, Heidenreich K, Williams JA (2016) Glucagon-like peptide-1 receptor is present in pancreatic acinar cells and regulates amylase secretion through cAMP. Am J Physiol Gastrointest Liver Physiol 310:G26–G33. https://doi.org/10.1152/ajpgi.00293.2015
Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Phys 273:G920–G927. https://doi.org/10.1152/ajpgi.1997.273.4.G920
Ivy AC, Oldberg E (1928) A hormone mechanism for gall-bladder contraction and evacuation. Am J Physiol 86:599–613
Jepsen SL, Grunddal KV, Wewer Albrechtsen NJ, Engelstoft MS, Gabe MBN, Jensen EP, Orskov C, Poulsen SS, Rosenkilde MM, Pedersen J, Gribble FM, Reimann F, Deacon CF, Schwartz TW, Christ AD, Martin RE, Holst JJ (2019) Paracrine crosstalk between intestinal L- and D-cells controls secretion of glucagon-like peptide-1 in mice. Am J Physiol Endocrinol Metab 317:E1081–E1093. https://doi.org/10.1152/ajpendo.00239.2019
Kaelberer MM, Buchanan KL, Klein ME, Barth BB, Montoya MM, Shen X, Bohorquez DV (2018) A gut-brain neural circuit for nutrient sensory transduction. Science 361. https://doi.org/10.1126/science.aat5236
Kanagawa K, Nakamura H, Murata I, Yosikawa I, Otsuki M (2002) Increased gastric acid secretion in cholecystokinin-1 receptor-deficient Otsuka Long-Evans Tokushima fatty rats. Scand J Gastroenterol 37:9–16. https://doi.org/10.1080/003655202753387284
Kaneko K, Fu Y, Lin HY, Cordonier EL, Mo Q, Gao Y, Yao T, Naylor J, Howard V, Saito K, Xu P, Chen SS, Chen MH, Xu Y, Williams KW, Ravn P, Fukuda M (2019) Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition. J Clin Invest 129:3786–3791. https://doi.org/10.1172/JCI126107
Kappe C, Zhang Q, Nystrom T, Sjoholm A (2014) Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells. Diabetol Metab Syndr 6:70. https://doi.org/10.1186/1758-5996-6-70
Kim SJ, Nian C, Karunakaran S, Clee SM, Isales CM, McIntosh CH (2012) GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS One 7:e40156. https://doi.org/10.1371/journal.pone.0040156
Kissileff HR, Pi-Sunyer FX, Thornton J, Smith GP (1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34:154–160. https://doi.org/10.1093/ajcn/34.2.154
Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya M, Inomata N, Osuye K, Nakazato M (2005) The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 146:2369–2375. https://doi.org/10.1210/en.2004-1266
Konner AC, Bruning JC (2012) Selective insulin and leptin resistance in metabolic disorders. Cell Metab 16:144–152. https://doi.org/10.1016/j.cmet.2012.07.004
Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2:1300–1304. https://doi.org/10.1016/s0140-6736(87)91194-9
Krieger JP, Arnold M, Pettersen KG, Lossel P, Langhans W, Lee SJ (2016) Knockdown of GLP-1 receptors in vagal afferents affects normal food intake and glycemia. Diabetes 65:34–43. https://doi.org/10.2337/db15-0973
Larraufie P, Martin-Gallausiaux C, Lapaque N, Dore J, Gribble FM, Reimann F, Blottiere HM (2018) SCFAs strongly stimulate PYY production in human enteroendocrine cells. Sci Rep 8:74–74. https://doi.org/10.1038/s41598-017-18259-0
Larraufie P, Roberts GP, McGavigan AK, Kay RG, Li J, Leiter A, Melvin A, Biggs EK, Ravn P, Davy K, Hornigold DC, Yeo GSH, Hardwick RH, Reimann F, Gribble FM (2019) Important role of the GLP-1 axis for glucose homeostasis after bariatric surgery. Cell Rep 26:1399–1408.e6. https://doi.org/10.1016/j.celrep.2019.01.047
Lebrun LJ, Lenaerts K, Kiers D, Pais de Barros J-P, Le Guern N, Plesnik J, Thomas C, Bourgeois T, Dejong CHC, Kox M, Hundscheid IHR, Khan NA, Mandard S, Deckert V, Pickkers P, Drucker DJ, Lagrost L, Grober J (2017) Enteroendocrine L cells sense LPS after gut barrier injury to enhance GLP-1 secretion. Cell Rep 21:1160–1168. https://doi.org/10.1016/j.celrep.2017.10.008
Lewis JE, Miedzybrodzka EL, Foreman RE, Woodward ORM, Kay RG, Goldspink DA, Gribble FM, Reimann F (2020) Selective stimulation of colonic L cells improves metabolic outcomes in mice. Diabetologia. https://doi.org/10.1007/s00125-020-05149-w
Li Y, Cao X, Li LX, Brubaker PL, Edlund H, Drucker DJ (2005) Beta-cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54:482–491. https://doi.org/10.2337/diabetes.54.2.482
Liang T, Dolai S, Xie L, Winter E, Orabi AI, Karimian N, Cosen-Binker LI, Huang YC, Thorn P, Cattral MS, Gaisano HY (2017) Ex vivo human pancreatic slice preparations offer a valuable model for studying pancreatic exocrine biology. J Biol Chem 292:5957–5969. https://doi.org/10.1074/jbc.M117.777433
Lieverse RJ, Jansen JB, Masclee AA, Rovati LC, Lamers CB (1994) Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide. Gut 35:501–505. https://doi.org/10.1136/gut.35.4.501
Llewellyn-Smith IJ, Reimann F, Gribble FM, Trapp S (2011) Preproglucagon neurons project widely to autonomic control areas in the mouse brain. Neuroscience 180:111–121. https://doi.org/10.1016/j.neuroscience.2011.02.023
Lu VB, Rievaj J, O'Flaherty EA, Smith CA, Pais R, Pattison LA, Tolhurst G, Leiter AB, Bulmer DC, Gribble FM, Reimann F (2019) Adenosine triphosphate is co-secreted with glucagon-like peptide-1 to modulate intestinal enterocytes and afferent neurons. Nat Commun 10:1029. https://doi.org/10.1038/s41467-019-09045-9
Lu VB, Gribble FM, Reimann F (2021) Nutrient-induced cellular mechanisms of gut hormone secretion. Nutrients 13. https://doi.org/10.3390/nu13030883
Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300:E1038–E1046. https://doi.org/10.1152/ajpendo.00665.2010
McIntyre N, Holdsworth CD, Turner DS (1964) New interpretation of oral glucose tolerance. Lancet 2:20–21. https://doi.org/10.1016/s0140-6736(64)90011-x
Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244–250. https://doi.org/10.1210/endo.140.1.6421
Meyer-Gerspach AC, Wolnerhanssen B, Beglinger B, Nessenius F, Napitupulu M, Schulte FH, Steinert RE, Beglinger C (2014) Gastric and intestinal satiation in obese and normal weight healthy people. Physiol Behav 129:265–271. https://doi.org/10.1016/j.physbeh.2014.02.043
Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8:738–742. https://doi.org/10.1038/nm727
Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L, Habener JF (1986) Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. J Biol Chem 261:11880–11889
Moller CL, Vistisen D, Faerch K, Johansen NB, Witte DR, Jonsson A, Pedersen O, Hansen T, Lauritzen T, Jorgensen ME, Torekov SS, Holst JJ (2016) Glucose-dependent insulinotropic polypeptide is associated with lower low-density lipoprotein but unhealthy fat distribution, independent of insulin: the ADDITION-PRO study. J Clin Endocrinol Metab 101:485–493. https://doi.org/10.1210/jc.2015-3133
Muller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ, Langhans W, Meier JJ, Nauck MA, Perez-Tilve D, Pocai A, Reimann F, Sandoval DA, Schwartz TW, Seeley RJ, Stemmer K, Tang-Christensen M, Woods SC, DiMarchi RD, Tschop MH (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72–130. https://doi.org/10.1016/j.molmet.2019.09.010
Mumphrey MB, Patterson LM, Zheng H, Berthoud HR (2013) Roux-en-Y gastric bypass surgery increases number but not density of CCK-, GLP-1-, 5-HT-, and neurotensin-expressing enteroendocrine cells in rats. Neurogastroenterol Motil 25:e70–e79. https://doi.org/10.1111/nmo.12034
Nasteska D, Harada N, Suzuki K, Yamane S, Hamasaki A, Joo E, Iwasaki K, Shibue K, Harada T, Inagaki N (2014) Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 63:2332–2343. https://doi.org/10.2337/db13-1563
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301–307. https://doi.org/10.1172/JCI116186
Nilsson O, Bilchik AJ, Goldenring JR, Ballantyne GH, Adrian TE, Modlin IM (1991) Distribution and immunocytochemical colocalization of peptide YY and enteroglucagon in endocrine cells of the rabbit colon. Endocrinology 129:139–148. https://doi.org/10.1210/endo-129-1-139
Nissen A, Christensen M, Knop FK, Vilsboll T, Holst JJ, Hartmann B (2014) Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab 99:E2325–E2329. https://doi.org/10.1210/jc.2014-2547
Nuzzo D, Baldassano S, Amato A, Picone P, Galizzi G, Caldara GF, Di Carlo M, Mule F (2019) Glucagon-like peptide-2 reduces the obesity-associated inflammation in the brain. Neurobiol Dis 121:296–304. https://doi.org/10.1016/j.nbd.2018.10.012
Orskov C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009–2013. https://doi.org/10.1210/endo-123-4-2009
Orskov C, Poulsen SS, Moller M, Holst JJ (1996) Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45:832–835. https://doi.org/10.2337/diab.45.6.832
Osinski C, Le Gleau L, Poitou C, de Toro-Martin J, Genser L, Fradet M, Soula HA, Leturque A, Blugeon C, Jourdren L, Hubert EL, Clement K, Serradas P, Ribeiro A (2021) Type 2 diabetes is associated with impaired jejunal enteroendocrine GLP-1 cell lineage in human obesity. Int J Obes 45:170–183. https://doi.org/10.1038/s41366-020-00694-1
Pais R, Rievaj J, Larraufie P, Gribble F, Reimann F (2016a) Angiotensin II type 1 receptor-dependent GLP-1 and PYY secretion in mice and humans. Endocrinology 157:3821–3831. https://doi.org/10.1210/en.2016-1384
Pais R, Rievaj J, Meek C, De Costa G, Jayamaha S, Alexander RT, Reimann F, Gribble F (2016b) Role of enteroendocrine L-cells in arginine vasopressin-mediated inhibition of colonic anion secretion. J Physiol 594:4865–4878. https://doi.org/10.1113/JP272053
Panaro BL, Yusta B, Matthews D, Koehler JA, Song Y, Sandoval DA, Drucker DJ (2020) Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. Mol Metab. https://doi.org/10.1016/j.molmet.2020.100990
Peiris M, Aktar R, Raynel S, Hao Z, Mumphrey MB, Berthoud HR, Blackshaw LA (2018) Effects of obesity and gastric bypass surgery on nutrient sensors, endocrine cells, and mucosal innervation of the mouse colon. Nutrients 10. https://doi.org/10.3390/nu10101529
Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects. J Clin Invest 46:1954–1962. https://doi.org/10.1172/JCI105685
Powley TL, Phillips RJ (2004) Gastric satiation is volumetric, intestinal satiation is nutritive. Physiol Behav 82:69–74. https://doi.org/10.1016/j.physbeh.2004.04.037
Psichas A, Glass LL, Sharp SJ, Reimann F, Gribble FM (2016) Galanin inhibits GLP-1 and GIP secretion via the GAL <sub>1</sub> receptor in enteroendocrine L and K cells. Br J Pharmacol 173:888–898. https://doi.org/10.1111/bph.13407
Rehfeld JF (2017) Cholecystokinin-from local gut hormone to ubiquitous messenger. Front Endocrinol (Lausanne) 8:47. https://doi.org/10.3389/fendo.2017.00047
Reidelberger RD, Hernandez J, Fritzsch B, Hulce M (2004) Abdominal vagal mediation of the satiety effects of CCK in rats. Am J Physiol Regul Integr Comp Physiol 286:R1005–R1012. https://doi.org/10.1152/ajpregu.00646.2003
Rhee NA, Wahlgren CD, Pedersen J, Mortensen B, Langholz E, Wandall EP, Friis SU, Vilmann P, Paulsen SJ, Kristiansen VB, Jelsing J, Dalboge LS, Poulsen SS, Holst JJ, Vilsboll T, Knop FK (2015) Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. Diabetologia 58:2254–2258. https://doi.org/10.1007/s00125-015-3696-3
Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM, Reimann F (2014) Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. Diabetes 63:1224–1233. https://doi.org/10.2337/db13-1440
Richards P, Pais R, Habib AM, Brighton CA, Yeo GS, Reimann F, Gribble FM (2016) High fat diet impairs the function of glucagon-like peptide-1 producing L-cells. Peptides 77:21–27. https://doi.org/10.1016/j.peptides.2015.06.006
Roberge JN, Gronau KA, Brubaker PL (1996) Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 137:2383–2388. https://doi.org/10.1210/endo.137.6.8641190
Roberts GP, Larraufie P, Richards P, Kay RG, Galvin SG, Miedzybrodzka EL, Leiter A, Li HJ, Glass LL, Ma MKL, Lam B, Yeo GSH, Scharfmann R, Chiarugi D, Hardwick RH, Reimann F, Gribble FM (2019) Comparison of human and murine enteroendocrine cells by transcriptomic and peptidomic profiling. Diabetes 68:1062–1072. https://doi.org/10.2337/db18-0883
Savage AP, Adrian TE, Carolan G, Chatterjee VK, Bloom SR (1987) Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers. Gut 28:166–170. https://doi.org/10.1136/gut.28.2.166
Schjoldager BT, Mortensen PE, Christiansen J, Orskov C, Holst JJ (1989) GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 34:703–708. https://doi.org/10.1007/BF01540341
Seimon RV, Brennan IM, Russo A, Little TJ, Jones KL, Standfield S, Wishart JM, Horowitz M, Feinle-Bisset C (2013) Gastric emptying, mouth-to-cecum transit, and glycemic, insulin, incretin, and energy intake responses to a mixed-nutrient liquid in lean, overweight, and obese males. Am J Physiol Endocrinol Metab 304:E294–E300. https://doi.org/10.1152/ajpendo.00533.2012
Shaffer EA (1982) The effect of vagotomy on gallbladder function and bile composition in man. Ann Surg 195:413–418. https://doi.org/10.1097/00000658-198204000-00006
Shankar SS, Shankar RR, Mixson LA, Miller DL, Pramanik B, O'Dowd AK, Williams DM, Frederick CB, Beals CR, Stoch SA, Steinberg HO, Kelley DE (2018) Native oxyntomodulin has significant glucoregulatory effects independent of weight loss in obese humans with and without type 2 diabetes. Diabetes 67:1105–1112. https://doi.org/10.2337/db17-1331
Shi X, Zhou F, Li X, Chang B, Li D, Wang Y, Tong Q, Xu Y, Fukuda M, Zhao JJ, Li D, Burrin DG, Chan L, Guan X (2013) Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 18:86–98. https://doi.org/10.1016/j.cmet.2013.06.014
Sisley S, Gutierrez-Aguilar R, Scott M, D'Alessio DA, Sandoval DA, Seeley RJ (2014) Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect. J Clin Invest 124:2456–2463. https://doi.org/10.1172/JCI72434
Song Y, Koehler JA, Baggio LL, Powers AC, Sandoval DA, Drucker DJ (2019) Gut-proglucagon-derived peptides are essential for regulating glucose homeostasis in mice. Cell Metab 30:976–986.e3. https://doi.org/10.1016/j.cmet.2019.08.009
Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A (2003) No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 27:450–456. https://doi.org/10.1038/sj.ijo.0802247
Steinert RE, Schirra J, Meyer-Gerspach AC, Kienle P, Fischer H, Schulte F, Goeke B, Beglinger C (2014) Effect of glucagon-like peptide-1 receptor antagonism on appetite and food intake in healthy men. Am J Clin Nutr 100:514–523. https://doi.org/10.3945/ajcn.114.083246
Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N (2017) Ghrelin, CCK, GLP-1, and PYY(3-36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97:411–463. https://doi.org/10.1152/physrev.00031.2014
Svane MS, Jorgensen NB, Bojsen-Moller KN, Dirksen C, Nielsen S, Kristiansen VB, Torang S, Wewer Albrechtsen NJ, Rehfeld JF, Hartmann B, Madsbad S, Holst JJ (2016) Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery. Int J Obes 40:1699–1706. https://doi.org/10.1038/ijo.2016.121
Thomas C, Gioiello A, Noriega L, Strehle A, Oury J, Rizzo G, Macchiarulo A, Yamamoto H, Mataki C, Pruzanski M, Pellicciari R, Auwerx J, Schoonjans K (2009) TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 10:167–177. https://doi.org/10.1016/j.cmet.2009.08.001
Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM (1998) Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 102:764–774. https://doi.org/10.1172/JCI942
Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM (2012) Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364–371. https://doi.org/10.2337/db11-1019
Toouli J, Hogan WJ, Geenen JE, Dodds WJ, Arndorfer RC (1982) Action of cholecystokinin-octapeptide on sphincter of Oddi basal pressure and phasic wave activity in humans. Surgery 92:497–503
Torekov SS, Harslof T, Rejnmark L, Eiken P, Jensen JB, Herman AP, Hansen T, Pedersen O, Holst JJ, Langdahl BL (2014) A functional amino acid substitution in the glucose-dependent insulinotropic polypeptide receptor (GIPR) gene is associated with lower bone mineral density and increased fracture risk. J Clin Endocrinol Metab 99:E729–E733. https://doi.org/10.1210/jc.2013-3766
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69–72. https://doi.org/10.1038/379069a0
Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A (2001a) A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol Metab 86:4382–4389. https://doi.org/10.1210/jcem.86.9.7877
Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A (2001b) The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25:1206–1214. https://doi.org/10.1038/sj.ijo.0801655
Vilsboll T, Krarup T, Madsbad S, Holst JJ (2003) Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Pept 114:115–121. https://doi.org/10.1016/s0167-0115(03)00111-3
Vrang N, Phifer CB, Corkern MM, Berthoud HR (2003) Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol Regul Integr Comp Physiol 285:R470–R478. https://doi.org/10.1152/ajpregu.00732.2002
Wang YB, de Lartigue G, Page AJ (2020) Dissecting the role of subtypes of gastrointestinal vagal afferents. Front Physiol 11:643. https://doi.org/10.3389/fphys.2020.00643
Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665–673. https://doi.org/10.1007/BF01316798
Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ (1997) The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40:597–601. https://doi.org/10.1136/gut.40.5.597
Williams DL, Baskin DG, Schwartz MW (2009) Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology 150:1680–1687. https://doi.org/10.1210/en.2008-1045
Williams EK, Chang RB, Strochlic DE, Umans BD, Lowell BB, Liberles SD (2016) Sensory neurons that detect stretch and nutrients in the digestive system. Cell 166:209–221. https://doi.org/10.1016/j.cell.2016.05.011
Woodward OR, Gribble FM, Reimann F, Lewis JE (2021) Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding. J Physiol. https://doi.org/10.1113/JP280581
Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR (2006) Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes 30:1729–1736. https://doi.org/10.1038/sj.ijo.0803344
Xie D, Cheng H, Hamrick M, Zhong Q, Ding KH, Correa D, Williams S, Mulloy A, Bollag W, Bollag RJ, Runner RR, McPherson JC, Insogna K, Isales CM (2005) Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 37:759–769. https://doi.org/10.1016/j.bone.2005.06.021
Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, Drucker DJ, Elmquist JK (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939–2946
Ye L, Mueller O, Bagwell J, Bagnat M, Liddle RA, Rawls JF (2019) High fat diet induces microbiota-dependent silencing of enteroendocrine cells. eLife 8. https://doi.org/10.7554/eLife.48479
Zhou J, Martin RJ, Tulley RT, Raggio AM, McCutcheon KL, Shen L, Danna SC, Tripathy S, Hegsted M, Keenan MJ (2008) Dietary resistant starch upregulates total GLP-1 and PYY in a sustained day-long manner through fermentation in rodents. Am J Physiol Endocrinol Metab 295:E1160–E1166. https://doi.org/10.1152/ajpendo.90637.2008
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Miedzybrodzka, E.L., Reimann, F., Gribble, F.M. (2022). The Enteroendocrine System in Obesity. In: Eckel, J., Clément, K. (eds) From Obesity to Diabetes. Handbook of Experimental Pharmacology, vol 274. Springer, Cham. https://doi.org/10.1007/164_2022_582
Download citation
DOI: https://doi.org/10.1007/164_2022_582
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-99994-0
Online ISBN: 978-3-030-99995-7
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)